Trial
NCT04250051
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Acute Myeloid Leukemia
Intervention
Cytarabine
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-01